Antisense Therapeutics chief executive Mark Diamond says the Melbourne biotech has hit a “very significant commercial milestone” after US regulators … Read More
The post Antisense Therapeutics receives FDA orphan designation for muscular dystrophy treatment appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.